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Introduction
The prevalence of diabetes worldwide was estimated at 
131 million in 2000 and is forecast to increase to 366 mil-
lion by 2030.1 In the UK, 2.8 million people were regis-
tered as having diabetes in 2010.2 Patients with diabetes 
are at increased risk of developing neuropathy, periph-
eral arterial disease and infections and are therefore at 
high risk of developing foot pathologies including ulcer-
ation. The results of cross-sectional community surveys 
in the UK showed that 7.4% of patients with diabetes had 
a history of active or previous foot ulcers.3 They have up 
to 25% lifetime risk of developing foot ulcers,4 which 
have a high risk of deteriorating and ultimately leading 
to major lower limb amputation. DFUs precede 84% of 
amputations, and nearly one in six patients with DFUs 
eventually require an amputation.5,6 The incidence of 
major lower limb amputation in people with diabetes is 
between 0.5 and 5.0 per 1,000 people and survival after a 
major lower limb amputation is poor, with a periopera-
tive mortality of 10–15% in the UK.3
Evaluation of DFUs includes vascular and neurologi-
cal examinations as well as accurate wound assessment. 
Successful management of DFUs consists of offloading 
with appropriate devices, management of infection, 
wound care including debridement and revascularisa-
tion when indicated. DFUs are usually associated with 
infection and inflammation which lead to oedema of 
the foot. Currently, most appliances use function only 
to alleviate mechanical load on ulcers and do not 
actively address the associated oedema, which can 
potentially be detrimental to ulcer healing. The objec-
tive of this article is to review the association of foot 
oedema and DFUs, including the role of appliances 
which reduce oedema.
Aetiology and classification of 
diabetic foot ulcers
The pathogenesis of DFUs is complex and has multiple 
contributing factors. The major underlying aetiologies of 
Diabetic foot disease and oedema
Teik K Ho,1 Richard D Leigh2 and Janice Tsui1 
Abstract
Diabetic foot ulcers (DFUs) are common and disabling, giving rise to significant morbidity and mortality as well as 
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diabetic foot ulceration are peripheral neuropathy, isch-
aemia, foot deformity and infections7 caused by the pro-
duction of advanced glycation end products secondary 
to hyperglycaemia. The incidence of neuroischaemic 
ulcers is 52.3%, neuropathic ulcers 36% and ischaemic 
ulcers 11.7%.8 Neuropathy includes sensory, motor and 
autonomic components. Deficient protective sensation 
leads to ulceration on high pressure areas; motor neu-
ropathy results in biomechanical abnormalities and 
autonomic neuropathy causes decreased sweating and 
dry skin which is more prone to hyperkeratosis and 
ulceration. Ischaemia is caused by peripheral arterial dis-
ease, resulting in decreased blood supply and tissue per-
fusion, which significantly compromise ulcer healing.
Peripheral arterial disease in patients with diabetes 
tends to be multifocal and commonly affects the infra-
popliteal vessels. Furthermore, disease progression is 
usually accelerated,9 and together with microvascular dis-
ease, results in poor outcomes. Endothelial dysfunction 
appears to be the main cause of both the macrovascular 
and microvascular disease and mechanisms which 
contribute to this include persistent hyperglycaemia, 
increased advanced glycation end-products, oxidative 
stress, endothelial inflammation and reduced nitric oxide 
activity.10,11 In addition, an increase in thromboxane A2, a 
vasoconstrictor and platelet aggregation agonist, has been 
associated with hyperglycaemia in diabetes, leading to an 
increased risk of plasma hypercoagulability.12
Impaired wound healing has also been implicated in 
patients with diabetes. The normal wound healing pro-
cess entails a complex interplay between connective tis-
sue formation, cellular activity, and growth factor 
activation. All three of these physiologic processes are 
altered in the diabetic state and contribute to the poor 
healing of DFUs.13 Instead of progressing through the 
normal stages of wound healing, it is now clear that dia-
betic ulcers remain in the inflammatory phase of the 
wound healing process. During this delay, there is a ces-
sation of epidermal growth and migration over the 
wound surface.14,15
Analysis of fluid from these chronic wounds has dem-
onstrated elevated levels of matrix metalloproteinases 
directly resulting in increased proteolytic activity and 
inactivation of the growth factors that are necessary for 
proper wound healing. Additionally, these chronic 
wounds have been found to exhibit deficiencies in growth 
factors and cytokines along with elevated levels of inhib-
itory proteases.13 Therefore, impaired wound healing is 
manifested in aberrant protein synthesis, cellular activity 
and growth factor secretion.
Classification systems have been developed to grade 
the severity of diabetic foot ulcers, provide prognosis on 
healing and aid in the formulation of treatment plans. 
The widely used Wagner classification for diabetic foot 
ulcers (table 1) assesses ulcer depth and the presence of 
osteomyelitis or gangrene.16 The University of Texas sys-
tem assesses ulcer depth, the presence of wound infec-
tion, and the presence of clinical signs of lower-extremity 
ischaemia.17 This system uses a matrix of grade on the 
horizontal axis and stage on the vertical axis (table 2). A 
prospective study of 194 patients comparing the two dia-
betic foot ulcer classifications concluded that the 
University of Texas classification is a better predictor of 
outcome.18 Increasing stage, regardless of grade, is asso-
ciated with increased risk of amputation and prolonged 
ulcer healing time. Recently, the Kobe classification has 
been proposed which focuses on the main aetiology of 
ulcers and proposes appropriate treatment (table 3)19. 
These classification systems illustrate the complexity 
and multi-aetiological nature of diabetic foot ulcers. 
Table 1. Wagner classification for diabetic foot ulcers
Grade Description of ulcer
0 intact skin in patients who are at risk
I superficial ulcers with exposed subcutaneous tissue
II exposed tendon and deep structures
III ulcers extend to the deep tissue and have either 
associated soft tissue abscess or osteomyelitis
IV ulcers include feet with partial gangrene
V feet ulcers with more extensive gangrenous tissue
Table 2. The University of Texas system
Grade Description of ulcer
0 an epithelialised wound
1 superficial ulcers not involving tendon, capsule, or bone
2 ulcers penetrate to tendon or capsule
3 ulcers penetrate to bone or joint
Within each wound grade there are four stages: stage A are clean 
wounds which are not infected and non-ischaemic; stage B ulcers are 
infected but not ischaemic; stage C ulcers are ischaemic but not infected; 
and stage D ulcers are both infected and ischaemic. Increasing stage, 
regardless of grade, is associated with increased risk of amputation and 
prolonged ulcer healing time.
Table 3.  Kobe classification
Type Aetiology and treatment of ulcer
1 ulcers are mainly caused by peripheral neuropathy and 
are treated by pressure relief
2 ulcers mainly result from peripheral arterial disease 
and the main treatment is revascularisation
3 ulcers have infection as the main aetiology and require 
early debridement
4 ulcers are caused by a combination of all three factors, 
i.e. peripheral neuropathy, peripheral arterial disease 
and infection, and are treated by revascularisation and 
debridement on a case-by-case basis
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However, none of the many grading systems take into 
account any associated oedema of the foot, illustrating 
that this remains a poorly understood aspect of DFUs.
Diabetic foot ulcers and oedema
The involvement of the microcirculation in diabetic 
microangiopathy contributes to foot ulceration. In addi-
tion, diabetic microangiopathy, characterised by an 
increase in skin flux at rest, decreased veno-arteriolar 
response, and increased capillary permeability results in 
oedema, reduced skin partial oxygen tension and 
increased carbon dioxide tension.20 In this condition, 
capillary exchange is altered and nutritional alterations 
eventually lead to skin lesions and ulcers.
The postural regulation of blood flow is impaired in 
patients with diabetic neuropathy. This disturbance is 
compatible with a loss of sympathetic vascular tone and 
arteriovenous shunting.21,22 In particular, the capability 
of effective precapillary vasoconstriction on standing is 
reduced. This exposes the capillary bed to a high hydro-
static load, resulting in hyperperfusion and increased 
shear force in the microcirculation on dependency which 
in turn leads to thickening of the capillary basement 
membrane and oedema of the feet and lower legs.23
In a prospective study of 314 patients with DFUs, the 
presence of oedema indicated a poorer prognosis24: 
peripheral oedema was more common in patients who 
required amputation (58%) or died (55%) than in patients 
with primary healing (26%, p<0.001). A tentative predis-
posing factor was identified in 95% of the patients, the 
most common factors being neuropathy, congestive heart 
failure, and previous deep venous thrombosis.
The principles of management of DFUs include 
proper assessment and treatment of different lesions of 
the foot, including infection control, debridement, 
wound management, revascularisation, other surgery, 
metabolic control and off-loading. Compression therapy 
may be used to reduce lower limb oedema to aid ulcer 
healing. Layered compression therapy and, more recently, 
diabetic socks with mild compression have been found 
to be safe and effective in diabetic patients with adequate 
or mildly reduced arterial blood supply.25,26 The follow-
ing sections further discuss the two methods associated 
with oedema reduction, offloading and compression 
therapy, in the management of DFUs.
Offloading devices in the 
management of DFUs
Appropriate offloading is a key component in the man-
agement of diabetic foot disease. The use of TCCs has 
been reported to result in excellent ulcer healing rates 
and associated with faster healing compared to other 
removable devices in a randomised controlled trial.27 
The TCC is considered to be the gold standard offload-
ing device for plantar neuropathic ulcers, yet it is still not 
widely used in clinical practice.28 It works by transmit-
ting load from the forefoot to the heel and directly to the 
leg via the cast walls.29 Its main disadvantage is that its 
application is time-consuming and often associated with 
a learning curve. Most centres do not have a physician or 
cast technician available with adequate training or expe-
rience to safely apply TCCs. Moreover, TCCs do not 
allow assessment of the foot or wound on a daily basis 
and are therefore often contraindicated in cases of soft 
tissue infections or osteomyelitis.
Iatrogenic ulceration where ulceration occurs whilst 
within the cast due to pressure or friction from cast 
materials is a concern, but the risks are reduced by proper 
casting techniques.30,31 Other patient complaints include 
impaired activities of daily living, such as difficulty sleep-
ing comfortably, and bathing difficulties while trying to 
avoid getting the cast wet, which reduce patient concord-
ance. Certain designs of TCCs may also exacerbate pos-
tural instability.32
Removable cast walkers are cast-like devices that are 
removable to allow inspection of the wound and applica-
tion of topical therapies. Further, removable cast walkers 
can be easily converted into instant total contact casts by 
wrapping the removable cast walker with cohesive band-
age or plaster of Paris.33 Wound healing efficacy of 
instant TCCs has been demonstrated to be comparable 
to TCCs in several randomized controlled trials.34,35
Although these standard offloading devices are 
believed to reduce oedema by enabling patients to remain 
relatively mobile, there has been no objective published 
data confirming this. Instead, immobilisation of the 
ankle with reduced function of the calf muscles which 
act as a venous pump, can theoretically impair venous 
return and potentially result in increased foot oedema.
Reducing oedema in the 
management of DFUs
In managing DFUs, foot elevation has generally been 
recommended to reduce oedema and prevent other 
sequential problems. However, foot elevation may 
decrease tissue oxygenation of the foot relative to the 
dependent position, which allows an increase in blood 
flow within the arterial system. The transcutaneous par-
tial oxygen tension has been shown to be reduced on foot 
elevation of patients with DFUs.36
In diabetic patients with lower limb oedema, mild 
compression therapy (18–25 mmHg) applied via socks 
or hosiery during the day was found to decrease calf and 
foot swelling by reducing oedema, without compromis-
ing vascularity in a study of 18 patients who have normal 
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arterial circulation.26 In the treatment of DFUs, compres-
sion therapy has been used effectively and safely to 
reduce oedema in a diabetic population with adequate 
arterial circulation whilst reduced compression was ben-
eficial in patients with arterial compromise in a prospec-
tive clinical case review involving 44 patients.25 Patients 
with adequate arterial circulation were treated with a 
four-layer compression bandage system while the highly 
elastic third layer was excluded in the patients who had 
compromised peripheral arterial circulation. Healing 
occurred in 81% of patients with adequate peripheral 
arterial circulation and 67% of patients with compro-
mised peripheral arterial circulation. There was no acute 
progression of lower limb ischaemia in the study. 
However, patients with diabetes have a high risk of devel-
oping peripheral arterial disease and many clinicians 
may be reluctant to use compression therapy.
The use of intermittent pneumatic compression by 
the A-V Impulse System has been shown to be safe and 
effective in other clinical areas such as the reduction of 
posttraumatic swelling and postoperative swelling fol-
lowing ankle and femoral neck fractures where the rate 
of proximal deep vein thrombosis was also reduced.37-39 
The A-V Impulse System was developed to mimic the 
natural physiological processes which maintain blood 
flow and has been shown to improve venous return and 
arterial blood flow in the extremities.40,41
The proposed mechanism of action is that intermit-
tent pneumatic compression leads to improved emptying 
of the lower extremity veins and lowered venous pressure 
which in turn results in an increase in arterio-venous 
pressure gradient and an increase in lower extremity 
arterial blood flow.42-44 In a cohort study of 40 lower 
limbs of 30 subjects, the application of intermittent 
pneumatic compression to calf and foot greatly enhanced 
popliteal artery blood flow. It was suggested that the flow 
increase is due to a dramatic drop in the peripheral vas-
cular resistance as the peak systolic and end diastolic 
flow velocities increase and the reverse-flow component 
diminishes.45 A direct reduction in peripheral resistance 
has also been postulated with intermittent pneumatic 
compression via release of nitric oxide, secondary to 
shear stress increase in the venous radicles. The action of 
diffused nitric oxide on adjacent arteriolar resistance 
vessels causes them to dilate transiently with concurrent 
flow enhancement.46
As discussed previously, there is evidence that in 
patients with diabetes, peripheral arterial disease is more 
aggressive, difficult to manage and associated with poorer 
outcomes.47 A systematic review demonstrated that 
an intermittent pneumatic compression programme 
appeared promising and may be used in patients 
with severe peripheral arterial disease who were not can-
didates for surgical or endovascular revascularization. 
Claudication distance, rest pain, and rates of limb salvage 
were improved across the spectrum of trials performed, 
associated with increased arterial blood flow, peak systolic 
velocity, end diastolic velocity and pulse volume.48 A small 
randomized study with 12 months follow-up (n=30) in 
patients with stable intermittent claudication concluded 
that walking distance improved in these patients.49 In 
addition to improved walking distance in stable claudi-
cants, a prospective randomised controlled study with 1 
year follow-up found an improvement in the ankle bra-
chial pressure index, which is a measurement of periph-
eral haemodynamics, and improvement in quality of life.50
A more recent study in patients with chronic lower 
limb ischaemia found a significant improvement in 
wound healing and limb salvage rates in the treated 
group. The intermittent pneumatic compression was 
delivered at an inflation pressure of 85–95mmHg, applied 
for 2 seconds with rapid rise (0.2 seconds), three cycles 
per minute, for three 2-hourly sessions per day.51
In DFUs, a double blind randomised controlled trial 
with 12 weeks follow-up also showed that oedema reduc-
tion by a pneumatic foot compression system increased 
the proportion of wound healing.52 Fifty-nine patients 
with diabetes were allocated to receive a functioning pul-
satile pneumatic foot compression system achieved by 
way of a pump and wrap system following debridement 
of infected foot ulcers. The system included a bladder 
containing a foot wrap and a pump that intermittently 
fired bursts of air through tubing to the wrap, thereby 
emptying the foot veins. This group was compared 
against a placebo group of 56 patients who received a 
non-functioning device. Patients were asked to use the 
device 8 hours a day, in addition to weekly standard 
wound care that included wound debridement and off-
loading. Patients treated with active foot compression 
had a 75% healing rate compared with 51% in the pla-
cebo group (p<0.02; odds ratio, 2.9; 95% confidence 
interval, 1.2–6.8) and a greater degree of oedema reduc-
tion as shown by mean foot circumference measure-
ments (23.8 vs. 25.7 cm, p<0.001) than those in the 
placebo group. However, a substantial number of patients 
in both groups found that it was inconvenient to have the 
device on and elevate their legs for 8 hours a day.
It would therefore appear that an intermittent pneu-
matic compression device with offloading property will 
have a potential combined effect of oedema reduction 
and offloading of high pressure areas, both of which are 
likely to improve diabetic foot ulcer healing. Randomised 
clinical trials, looking at a range of DFUs, are warranted 
to assess these effects on ulcer healing.
Conclusion
Treatment of oedema may further improve the outcomes 
of DFUs, over and above standard therapy. A device 
which is comfortable to increase concordance, able to 
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provide intermittent pneumatic compression to actively 
reduce oedema, and allow offloading can be useful for 
this purpose but further investigation will be required to 
provide a strong level of evidence.
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